Présentation de l'entreprise
MetaVia Inc. operates as a clinical-stage biotechnology enterprise dedicated to the development of novel pharmaceutical interventions specifically designed to address cardiometabolic diseases. The company's primary scientific focus involves the creation of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist that holds development optionality for use as either a standalone therapy or in combination regimens, currently positioned within Phase 2a clinical trials. This entity functions within the broader Healthcare sector, specifically the Biotechnology industry, which implies a high-risk, high-reward environment characterized by significant research and development expenditures and reliance on successful clinical trial outcomes to achieve commercialization. The organization maintains a minimal operational footprint with a workforce of 8 employees, and its market capitalization stands at $6.26M, reflecting a pre-revenue or early-stage valuation typical of clinical biotech firms where revenue and earnings figures are currently N/A.
Santé financière
The financial performance of MetaVia Inc. is defined by its status as an unprofitable clinical-stage entity, reporting a Net Income of $-12,973,000 and an EBITDA of $-13,689,000 over the trailing twelve months, while Revenue remains N/A. The substantial gap between the reported revenue of N/A and the significant net loss of $-12,973,000 reveals a cost structure dominated entirely by operating expenses required to advance clinical programs rather than sales activities. Free Cash Flow is recorded at $-11,278,500, indicating that the company is consuming cash to fund its research and development pipeline, which limits immediate financial flexibility but is a standard characteristic for pre-commercial biotechnology firms. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, a figure that indicates the company has not yet generated revenue to establish a positive margin structure or that revenue is insufficient to cover operating costs in the traditional sense. Regarding liquidity and leverage, the company holds $10.31M in cash against a debt level of $210,000, resulting in a Debt to Equity ratio of 3.94, which suggests a highly leveraged balance sheet relative to equity, though the low absolute debt amount implies solvency is not the primary concern compared to cash burn. The Current Ratio stands at 1.93, indicating that current assets are nearly double current liabilities, which suggests adequate short-term liquidity to meet obligations despite the cash burn rate. Return on Equity is -195.6% and Return on Assets is -62.6%, metrics that reveal management is currently generating negative returns on shareholder capital and assets, consistent with the strategic reinvestment phase of a clinical-stage biotechnology company.
Évaluation de la valorisation
The trailing P/E ratio and forward P/E for MetaVia Inc. are both listed as N/A, which implies that the lack of positive earnings makes traditional price-to-earnings valuation models inapplicable and suggests that any expected earnings trajectory is entirely dependent on the successful completion of clinical trials. The Price to Book ratio is 0.53, indicating that the market values the company at significantly less than its book value, a common valuation characteristic for distressed or unprofitable biotechnology assets where future cash flows are highly uncertain. The Price to Sales ratio is N/A and the EV/EBITDA stands at 0.28, suggesting that alternative valuation metrics are heavily weighted towards enterprise value adjustments given the negative earnings, though the low EV/EBITDA of 0.28 reflects the extreme leverage or negative earnings normalization in the denominator. The stock's price action over the last year shows a 52-Week High of $23.10 and a 52-Week Low of $1.17; without a specific current share price provided in the available facts, the valuation range indicates extreme volatility, with the asset trading at a point that must be evaluated against this wide historical spread. The Beta value is 0.34, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting that the company's price movements are less sensitive to general market fluctuations, a trait often seen in small-cap biotechnology stocks with idiosyncratic growth drivers.
Growth & Income
The Revenue Growth year-over-year and Earnings Growth year-over-year are both N/A, precluding a direct comparison of earnings growth versus revenue growth rates at this stage of the company's lifecycle. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that the organization does not distribute income to shareholders but instead retains all available resources to fund its clinical development programs. The 0.0% payout ratio is theoretically sustainable given the absence of dividends, but the company's financial reality dictates that earnings are negative, meaning the focus is strictly on capital allocation towards R&D rather than shareholder returns. Consequently, the overall growth and income profile of MetaVia Inc. is characterized by zero current income distribution and undefined growth rates due to the absence of commercial revenue, leaving the company's future value contingent entirely on the clinical success of its pipeline and its ability to secure further financing.